Abstract
The current treatment regimen against drug susceptible tuberculosis (DS-TB) was defined by the 1980s. Since then the emergence of the global HIV pandemic and the escalation of drug resistant (DR-) forms of TB have presented new challenges for therapeutic research. Priority goals include shortening DS-TB treatment, improving DR-TB treatment and making combined TB-HIV therapy easier. To help achieve these goals, a range of new drugs and treatment strategies are currently being evaluated. Phase IIb and III clinical trials are ongoing to assess combinations involving the high-dose rifamycins, the 8-methoxyquinolones, a diarylquinoline (bedaquiline) and the nitroimidazoles. Other compounds (e.g. novel oxazolidinones and ethylenediamines) are at earlier stages of clinical development. Overall, there are grounds for optimism that recent advances will contribute towards achievement of new treatment regimens in the foreseeable future. However, long-term investment, political commitment and scientific endeavour are crucial to ensure that progress is sustained and the benefits of recent advances reach those in the greatest need.
Keywords: Bedaquiline (TMC-207), Delamanid (OPC-67683), Gatifloxacin, Moxifluxacin, PA-824, Rifampicin, Rifapentine, sterilising activity.
Current Respiratory Medicine Reviews
Title:New Drugs and Treatment Regimens
Volume: 9 Issue: 3
Author(s): Derek J. Sloan, Geraint R. Davies and Saye H. Khoo
Affiliation:
Keywords: Bedaquiline (TMC-207), Delamanid (OPC-67683), Gatifloxacin, Moxifluxacin, PA-824, Rifampicin, Rifapentine, sterilising activity.
Abstract: The current treatment regimen against drug susceptible tuberculosis (DS-TB) was defined by the 1980s. Since then the emergence of the global HIV pandemic and the escalation of drug resistant (DR-) forms of TB have presented new challenges for therapeutic research. Priority goals include shortening DS-TB treatment, improving DR-TB treatment and making combined TB-HIV therapy easier. To help achieve these goals, a range of new drugs and treatment strategies are currently being evaluated. Phase IIb and III clinical trials are ongoing to assess combinations involving the high-dose rifamycins, the 8-methoxyquinolones, a diarylquinoline (bedaquiline) and the nitroimidazoles. Other compounds (e.g. novel oxazolidinones and ethylenediamines) are at earlier stages of clinical development. Overall, there are grounds for optimism that recent advances will contribute towards achievement of new treatment regimens in the foreseeable future. However, long-term investment, political commitment and scientific endeavour are crucial to ensure that progress is sustained and the benefits of recent advances reach those in the greatest need.
Export Options
About this article
Cite this article as:
Sloan J. Derek, Davies R. Geraint and Khoo H. Saye, New Drugs and Treatment Regimens, Current Respiratory Medicine Reviews 2013; 9 (3) . https://dx.doi.org/10.2174/1573398X113099990017
DOI https://dx.doi.org/10.2174/1573398X113099990017 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The β-Ketoacyl-ACP Synthase from Mycobacterium tuberculosis as Potential Drug Targets
Current Medicinal Chemistry The GFP Viability Assay for Cryobiology Applications: A Mechanistic Understanding
Current Tissue Engineering (Discontinued) Curcumin: A Dietary Phytochemical for Targeting the Phenotype and Function of Dendritic Cells
Current Medicinal Chemistry IP6 (Inositol Hexaphosphate) as a Signaling Molecule
Current Signal Transduction Therapy Synthesis, Molecular Docking, in vitro Antiproliferative and Antioxidant Activity of Novel Pyrrolidinyl-Carbazole Derivatives
Current Organic Synthesis Microarray Analysis of Whole Genome Expression of Intracellular Mycobacterium tuberculosis
Current Molecular Medicine Dealing with the Substance Abuse Epidemic and Infective Endocarditis:Clinical, Immunologic and Pathogenetic Aspects
Current Vascular Pharmacology ent-Abietane Lactones from Euphorbia
Mini-Reviews in Medicinal Chemistry Recent Achievements in the Chemistry of 1,2-Diazines
Current Organic Chemistry Artificial Neural Network Analysis of Pharmacokinetic and Toxicity Properties of Lead Molecules for Dengue Fever, Tuberculosis and Malaria
Current Computer-Aided Drug Design Anti-Inflammatory Drugs in Psychiatry
Inflammation & Allergy - Drug Targets (Discontinued) Preparation and Characterization of Solid Lipid Nanoparticles-A Review
Current Drug Discovery Technologies Dietary Habits of Mongolian People, and Their Influence on Lifestyle-Related Diseases and Early Aging
Current Aging Science Monoclonal Antibodies in Allergy; Updated Applications and Promising Trials
Recent Patents on Inflammation & Allergy Drug Discovery The Cell-Wall Core of Mycobacterium tuberculosis in the Context of Drug Discovery.
Current Topics in Medicinal Chemistry A Review on Nuclear Imaging as a Promising Modality for Efficient Diagnosis of Tuberculosis
Current Medical Imaging Editorial (Thematic Issue: Techniques and Application in Metabolomics: From Metabolite Profiling to Spatial Distribution)
Current Metabolomics Molecular Biological Roles of Ursolic Acid in the Treatment of Human Diseases
Current Bioactive Compounds CXCR3 Axis: Role in Inflammatory Bowel Disease and its Therapeutic Implication
Endocrine, Metabolic & Immune Disorders - Drug Targets T-Lymphocytes: A Target for Stimulatory and Inhibitory Effects of Zinc Ions
Endocrine, Metabolic & Immune Disorders - Drug Targets